Notice: Undefined index: H2020-EU.3.2.4.2. in /var/www/vhosts/fabiodisconzi.com/httpdocs/open-eu/h2020/funzioni-specifiche-h2020.php on line 565
EU H2020 Project "PHARMA-FACTORY (Building the product pipeline for commercial demonstration of Plant Molecular..)": description, partecipants, costs and EC-fundings
Opendata, web and dolomites

Pharma-Factory SIGNED

Building the product pipeline for commercial demonstration of Plant Molecular Factories

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Pharma-Factory project word cloud

Explore the words cloud of the Pharma-Factory project. It provides you a very rough idea of what is the project "Pharma-Factory" about.

platform    acceptance    molecular    biotechnology    regulatory    smes    diagnostic    farming    public    competitiveness    tools    economic    clear    involvement    bio    virus    plant   

Project "Pharma-Factory" data sheet

The following table provides information about the project.

Coordinator
ST GEORGE'S HOSPITAL MEDICAL SCHOOL 

Organization address
address: Cranmer Terrace
city: LONDON
postcode: SW17 0RE
website: http://www.sgul.ac.uk/

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 9˙254˙335 €
 EC max contribution 8˙286˙008 € (90%)
 Programme 1. H2020-EU.3.2.4.2. (H2020-EU.3.2.4.2.)
 Code Call H2020-BB-2017-1
 Funding Scheme /IA
 Starting year 2017
 Duration (year-month-day) from 2017-11-01   to  2021-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ST GEORGE'S HOSPITAL MEDICAL SCHOOL UK (LONDON) coordinator 1˙715˙885.00
2    FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. DE (MUNCHEN) participant 624˙547.00
3    Teknologian tutkimuskeskus VTT Oy FI (Espoo) participant 560˙827.00
4    UNIVERSITE DE ROUEN NORMANDIE FR (MONT SAINT AIGNAN CEDEX) participant 531˙500.00
5    UNIVERSITY COLLEGE LONDON UK (LONDON) participant 524˙226.00
6    THE UNIVERSITY OF THE ARTS LONDON UK (LONDON) participant 520˙000.00
7    UNIVERSIDAD DE LLEIDA ES (LLEIDA) participant 519˙902.00
8    TRANSALGAE ISRAEL LTD IL (TEHOVOT) participant 519˙750.00
9    AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS ES (MADRID) participant 519˙710.00
10    JOHN INNES CENTRE UK (NORWICH) participant 509˙982.00
11    DIAMANTE SRL IT (VERONA) participant 499˙625.00
12    ROOT LINES TECHNOLOGY FR (AMIENS) participant 455˙700.00
13    ALBAJUNA THERAPEUTICS ES (BADALONA) participant 400˙312.00
14    LEAF SYSTEMS INTERNATIONAL LIMITED UK (NORWICH) participant 384˙040.00

Mappa

 Project objective

Plant Molecular Farming is the manufacture of high-value products using plant biotechnology. Pharma-Factory was conceived and designed by SMEs active in the field to produce medical, veterinary and diagnostic products. Product-driven work packages and a collective approach to public involvement and regulatory consultation will accelerate commercialisation of new bio-products, and increase the competitiveness of European bio-industry by resolving technical, social and economic bottlenecks in this field. All parts of the work programme are addressed by refining technologies using new synthetic biology tools, demonstrating manufacturing advantages for individual products, identifying a clear regulatory path for each platform technology, developing clear business cases with supporting techno-economic evaluations and life cycle analyses and improving public engagement and acceptance. Five SMEs will develop products that include arylsulfatase B (for human enzyme replacement therapy), a vaccine for infectious spleen and kidney necrosis virus in fish, two highly potent HIV neutralising antibody-based fusion proteins and plant chimaeric virus-like-particles for a diagnostic kit. In collaboration with academic partners they will advance six plant molecular farming platforms for this purpose, including whole plants, algae, hairy roots and plant cell culture, by designing and developing new tools to increase the competitiveness, utility and versatility of each platform. All companies will reach Technology Readiness Level 5 within the lifetime of the project, with two products to be commercialized. The project provides a unique opportunity to improve public involvement with plant biotechnology at a European-wide level. A work package has been dedicated to gain maximal impact by engaging with all stakeholders – from scientists to government and the public at large, developing new tools to facilitate communication, to help understand and reduce barriers to acceptance.

 Work performed, outcomes and results:  advancements report(s) 

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PHARMA-FACTORY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PHARMA-FACTORY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.2.4.2.)

Pharma-Factory (2017)

Building the product pipeline for commercial demonstration of Plant Molecular Factories

Read More